Product logins

Find logins to all Clarivate products below.


Supportive Care in Oncology | Physician & Payer Forum | US | 2015

Is There a Disconnect Between Physician and Payer Perceptions of Therapies Across Key Indications?

The treatment of both solid and hematological cancers is associated with a wide range of serious side effects, including febrile neutropenia, anemia, nausea and vomiting, and oral mucositis. In addition to being life threatening, these side effects have significant detrimental impact on patients’ quality of life and often require dose delays, dose reductions, or cessation of cancer treatment, thereby compromising outcomes. As a result, the optimal treatment of chemotherapy-related side effects using supportive care therapies is an integral part of good cancer patient care. Recently approved biosimilar filgrastim (Sandoz’s Zarxio), the first biosimilar to receive FDA approval, will drive down price, assuming that both payers and physicians are receptive to biosimilar therapies. Anemia associated with both cancer and its treatment has a huge impact on patients, but some physicians remain reluctant to prescribe erythropoiesis-stimulating agents (ESAs), because of their toxicity profile and negative effect on outcomes.

Preventative treatment of chemotherapy-induced nausea and vomiting has become a routine component of treatment for specific chemotherapy regimens; however, many patients still suffer symptoms, and agents have been costly. The arrival of generic drugs and innovative formulations should improve access and symptom control for patients if payers facilitate access to these therapies. Management of oral mucositis, especially for patients with squamous cell cancer of the head and neck undergoing radiotherapy/chemoradiotherapy, is inadequate and leaves patients with terrible symptoms and poor quality of life. Despite suboptimal treatments, access to current therapies is variable and comes with substantial patient out-of-pocket costs. Across these diverse supportive care indications run the themes of patient access, increasing costs, and restrictive measures.

Related Market Assessment Reports

Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…